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ABSTRACT
Given the importance of appropriate diagnosis and appropriate assessment of cutaneous symptoms in treat-
ment of atopic dermatitis, the basics of treatment in this guideline are composed of (1) investigation and coun-
termeasures of causes and exacerbating factors, (2) correction of skin dysfunctions (skin care), and (3) phar-
macotherapy, as three mainstays. These are based on the disease concept that atopic dermatitis is a inflam-
matory cutaneous disease with eczema by atopic diathesis, multi-factorial in onset and aggravation, and ac-
companied by skin dysfunctions. These three points are equally important and should be appropriately com-
bined in accordance with the symptoms of each patient. In treatment, it is important to transmit the etiological,
pathological, physiological, or therapeutic information to the patient to build a favorable partnership with the pa-
tient or hisher family so that they may fully understand the treatment. This guideline discusses chiefly the ba-
sic therapy in relation to the treatment of this disease. The goal of treatment is to enable patients to lead an un-
interrupted social life and to control their cutaneous symptoms so that their quality of life (QOL) may meet a sat-
isfactory level.
The basics of treatment discussed in this guideline are based on the “Guidelines for the Treatment of Atopic
Dermatitis 2008” prepared by the Health and Labour Sciences Research and the “Guidelines for the Manage-
ment of Atopic Dermatitis 2012 (ADGL2012)” prepared by the Atopic Dermatitis Guidelines Advisory Commit-
tee, Japanese Society of Allergology in principle. The guidelines for the treatment of atopic dermatitis are sum-
marized in the “Japanese Guideline for the Diagnosis and Treatment of Allergic Disease 2013” together with
those for other allergic diseases.
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1. DefinitionDisease Concept, Pathophy-
siologyEtiology of Atopic Dermatitis
1.1. Definition and Disease Concept
The guidelines adopt the definition (concept)1 of the
Japanese Dermatological Association on atopic der-
matitis that states “atopic dermatitis is a disease with
repeated exacerbation and remission, chiefly charac-
terized by eczema with itch, mostly exhibited by pa-
tients with atopic diathesis.”
Note: Atopic diathesis. (i) Personal or family his-
tory of bronchial asthma, allergic rhinitis and con-
junctivitis, andor atopic dermatitis andor (ii) predis-
position to overproduction of immunoglobulin E
(IgE) antibodies. Patients with eczematous lesions
that develop during infancy or childhood and persist
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without complete recovery or repeatedly recur even
in adulthood.
1.2. Pathophysiology
1.2.1. Inflammatory mechanism
Atopic dermatitis is a disease included in the ec-
zemadermatitis group. The dominant mechanisms
of atopic dermatitis in lesional skin are governed by
Th2 cell-related cytokines such as IL-4 and IL-13, and
chemokines such as TARC (thymus and activation-
regulated chemokine) and eotaxin.2 Among such
chemokines, the so-called Th2 chemokines such as
TARCCCL17 and MDCCCL22 deserve special at-
tention. These chemokines are chemotactic for Th2
cells expressing the chemokine receptor CCR4. Ac-
cordingly, Th2 cells are usually observed at an ec-
zematous site.3
This is, however, a pathology in the acute stage,
and Th1 cells producing IFN-γ and IL-12 are report-
edly dominant in the chronic stage.4 Langerhans cells
and mast cells are involved in the inflammatory re-
sponse by expressing a high affinity IgE receptor
(FcεRI) that causes antigen presenting cells and mast
cells to release histamine, cytokines, etc.
The Th2 cytokines IL-4 and IL-13 stimulate fibro-
blasts to produce periostin, protein causing keratino-
cytes to produce TSLP,5 which induces TARCCCL17
production by dendritic cells.6 Serum TARCCCL17
levels are useful as a short-term disease marker for
atopic dermatitis and the test is covered by health in-
surance. Research on Th17 as a new effector cell for
allergic reactions7 and on Treg (regulatory T cell)8
that controls overreaction is also in progress.
In an eczematous lesion of atopic dermatitis, antim-
icrobial peptides (defensins, cathelicidins, etc.) are in-
hibited from being expressed by keratinocytes.9
1.2.2. Skin dysfunctions
Expression of ceramide10 and filaggrin11 decreases in
skin with atopic dermatitis, particularly in lesions,
and is considered as a primary cause of barrier dys-
functions. It is also considered as a secondary phe-
nomenon associated with inflammation and as a
cause of atopic dermatitis. Atopic dermatitis is accom-
panied by an acute itch allegedly due to a lowered
threshold of itch. Involvement of IL-31 has been re-
ported as a cause of the above.12
It is often experienced that itch due to atopic der-
matitis cannot be well controlled with antihistamines.
Histamine, substance P, and their receptors have
been shown to play an important role in itch at the pe-
ripheral level. Recently, the role of endogenous
opioids such as beta-endorphin and their receptors in
itching at the central level has received attention. It
has been reported that morphine induces itch via
GRP receptors.13
1.3. Etiology
Atopic dermatitis is caused by combination of genetic
and environmental factors.
1.3.1. Genetic factors
Regarding genetic factors, some etiological candidate
genes associated with atopic dermatitis have been re-
ported. Major candidate genes reported to date in-
clude CTLA4, IL18, TLR9, CD14, CARD4, PHF11,
TLR2, SCCE, MCC, IL4R, GM-CSF, TIM1, CARD15,
GSTT1, SPINK5, eotaxin, TGFβ1, IL13, RANTES,
IL4, and FcεRIβ. In a recent GWAS of Japanese sam-
ples, “2q12 (IL1RL1IL18R1IL18RAP),” “3p21.33
(GLB1),” “3q13.2 (CCDC80),” “6p21.3 (MHC re-
gion),” “7p22 (CARD11),” “10q21.2 (ZNF365),” “11p
15.4 (OR10A3NLRP10),” and “20q13 (CYP24A1
PFDN4) ” have been reported as candidate genes.14
1.3.2. Etiological and exacerbating factors
A wide variety of etiological and exacerbating factors
has been proposed, with the importance level of each
varying among individual patients. In addition, inflam-
mation associated with this disease will be elucidated
by both allergic and non-allergic mechanisms. Eti-
ological and exacerbating factors vary among age
groups. While the dominant factors in the first half of
childhood include foods, sweating, physical irritation
(including scratching), environmental factors, mi-
crobesfungi, the dominant factors in the second half
of childhood to adulthood include environmental fac-
tors, sweating, physical irritation (including scratch-
ing), microbesfungi, contact allergens, stress, and
foods (Fig. 1).
It is commonly experienced that sweating induces
itch leading to the aggravation of atopic dermatitis
symptoms. Clinically, psychological stress is well
known to exacerbate atopic dermatitis symptoms. Al-
though the mechanism is mostly unknown, an in-
crease in sensory nerve fibers containing substance P
and CGRP is observed at inflammatory skin sites of
patients with this disease.15
2. Epidemiology of Atopic Dermatitis
2.1. Global Prevalence of Atopic Dermatitis and
Its Changes
An epidemiological survey (Phase I) was conducted
from 1994 to 1996 by the International Study of
Asthma and Allergies in Childhood (ISAAC).16 The
global prevalence in 6-7 year olds ranged from 1.1% in
Iran to 18.4% in Sweden and was 7.3% on average. The
global prevalence in 13-14 year olds ranged from 0.8%
in Albania to 17.7% in Nigeria and was 7.4% on aver-
age. The highest prevalence was seen mostly in in-
dustrial nations including Sweden, Finland, UK, Ja-
pan, Australia, and New Zealand. In the epidemiologi-
cal survey (Phase II) conducted from 2001 to 2003 by
the ISAAC, few nations showed a significant decrease
in the prevalence in 6-7 year olds compared with their
Atopic Dermatitis
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Fig.　1　Causes and exacerbating factors. Since causes and exacerbating factors vary among patients, 
care should be taken to identify them sufficiently for each patient before taking removal measures. Modi-
fi ed from Ministry of Health and Welfare, Japan. [Guidelines for the Treatment of Atopic Dermatitis 2008] 
(in Japanese).
Reference
Note
Abnormal skin functions seen in atopic dermatitis
Atopic dermatitis should be treated based on a good understanding of abnormal skin functions.
●Decreased water retentivity/barrier functions ●Lowered itch threshold ●Susceptibility to infection
Younger than
2 years old 
2-12 years old
13 years and
older to adult 
○Foods (egg, cow’s milk, wheat, 
etc.) 
○sweat ○drying ○scratching
○physicochemical irritation 
(slaver, soap, detergent, 
rubbing of clothes, etc.) 
○mites, dust, pets, etc.
○microbes/fungi etc.
○sweat ○drying ○scratching
○physicochemical irritation 
(soap, detergent, rubbing of 
clothes, etc.) 
○microbes/fungi
○mites, dust, pets, etc.
○stress
○foods (egg, cow’s milk, wheat, 
etc.)  etc.
prevalence reported in Phase I of the survey.17 In
terms of the age group of 13-14 year olds, some of the
advanced nations with a high prevalence reported in
Phase I (UK, New Zealand, etc.) showed a decrease
in Phase II.
2.2. Epidemiological Survey in Japan
A nationwide prevalence survey was conducted in Ja-
pan from 2000 to 2008 using the medical examination
data from public health centers, elementary schools,
and universities. Figure 2 shows the prevalence by
age groups. In addition, a prevalence survey on the
adult atopic dermatitis was performed using the
medical examination for 2,943 personnel of 2 univer-
sities18 (Fig. 2). The data on occurrence and progres-
sion of infantile atopic dermatitis is provided by a re-
port based on a follow-up study of infants of 4 months
to 3 years old performed in the Health and Labour
Sciences Research, from 2006 to 2008, in Yokohama
City, Chiba City, and Fukuoka City. The report shows
that 16.2% of ordinary infants, who received a medical
examination at 4 months of age, developed atopic der-
matitis. Atopic dermatitis remitted in 50% of the 4-
month-old patients before the age of 18 months, indi-
cating an extremely dynamic change in progression
of atopic dermatitis in infancy.19 This survey showed
a cumulative incidence rate before 3 years of age of a
little more than 30%, similar to reports from overseas
(Fig. 3).
3. Diagnosis of Atopic Dermatitis
3.1. Diagnostics Criteria for Atopic Dermatitis
(1) Diagnostic criteria proposed by Hanifin and Ra-
jka: The diagnostic criteria of Hanifin and Rajka are
internationally most popular.
(2) Diagnostic criteria proposed by the Japanese
Dermatological Association: The Japanese Derma-
tological Association developed diagnostic criteria in
1994, which was partly revised in 2008 (Table 1). Us-
ing these criteria, all diseases that meet the 3 require-
ments of itch, characteristic rashes and distribution,
and chronicrecurrent progression, will be diagnosed
as atopic dermatitis irrespective of the severity of
symptoms.1
3.2. Laboratory Data Used as a Reference for Di-
agnosis
(1) Serum total IgE level: A high serum total IgE
Katayama I et al.
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Fig.　2　Prevalence of atopic dermatitis by age groups in the fi scal year of 1996-2008. 4 months old from: Hok-
kaido, Kanto, Chubu, Kinki, Chugoku, Shikoku, and Kyushu (seven districts, n = 2744). Children with 1.5 years 
old, 3 years old , 1st grade of elementary, 6th grade of elementary from: Hokkaido, Tohoku, Kanto, Chubu, Kinki, 
Chugoku, Shikoku, and Kyushu (eight districts, n = 6424). University students from: University of Tokyo, Kinki 
University, Hiroshima University (n = 8317). Adult (20s to 60s) from: Personnel of University of Tokyo and Kinki 
University (n = 2943). Modifi ed from Ministry of Health and Welfare, Japan. [Guidelines for the Treatment of 
Atopic Dermatitis 2008] (in Japanese).
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level is observed in approximately 80% of patients
with atopic dermatitis. It is also reportedly signifi-
cantly correlated with the severity (the later dis-
cussed SCORing Atopic Dermatitis [SCORAD] sever-
ity index).
(2) Blood eosinophil count: Eosinophilia is seen in
blood and the rash tissue of many but not all patients.
Because it changes more rapidly than IgE, it serves
as an index to assess changes of the disease condi-
tion.
(3) Specific IgE antibody titer: Patients with atopic
dermatitis are apt to produce IgE antibodies in re-
sponse to various allergens such as mites, foods, and
pets and often show positive reactions to multiple al-
lergens. Preventing exposure to the allergens that
have been proven positive is expected to improve or
prevent exacerbation of rashes.
(4) Serum TARC level: The serum level of TARC, a
Th2 chemokine, has been shown to sensitively reflect
the short-term condition of atopic dermatitis and is re-
garded as a useful auxiliary marker to assess the se-
verity of atopic dermatitis.
(5) Others: Laboratory data reportedly used as a
reference for disease conditions include lactate dehy-
drogenase (LDH). The soluble IL-2R level, which is
high in skin lymphoma, is a useful assessment tool.
3.3. Severity Criteria for Atopic Dermatitis
(1) SCORAD: SCORAD is an international severity
criterion that has been most popularly adopted in the
English written literature at present. These criteria
grade the rash areas, severity of rash elements such
as erythema, edemapapule, exudationcrust, licheni-
fication, scratch marks, xerosis cutis, and subjective
symptoms such as itch, and insomnia, by weighting
them at a ratio of approximately 2 : 6 : 2.
(2) Atopic dermatitis severity classification of the
Japanese Dermatological Association: This severity
criteria assesses severity based on the total scores of
3 rash elements (erythemaacute papule, moisten-
ingcrust, chronic papuletuberclelichenification)
and rash areas of the body divided into the following
5 sections: head and neck, anterior body trunk, poste-
rior body trunk, upper limbs, and lower limbs.20
Atopic Dermatitis
Allergology International Vol 63, No3, 2014 www.jsaweb.jp 381
Fig.　3　Individual follow-up analysis of symptom onset/progression of 
atopic dermatitis in patients aged 4 months to 3 years (fi scal years sur-
veyed: FY2006-FY2008).
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Cumulative incidence rate up to 3 years of age: 31.6%
Physical examination of 
4 month olds
Physical examination of 
1 year 6 month olds
Physical examination of 
3 year olds
Yokohama:  851 patients
Chiba:  523 patients
Fukuoka:  404 patients
Total:  1,778 patients
(3) Severity indicators: Although the above-ment-
ioned severity criteria are more objective than the
conventional criteria, they are difficult to use in daily
medical practice because of too many endpoints. Ac-
cordingly, the “Guidelines for the Treatment of
Atopic Dermatitis 2008” of the Health and Labour Sci-
ences Research proposes a simpler indicator of sever-
ity (Table 2). This indicator measures severity by as-
sessing both the severity and the spread of the rash
and defines mild rashes and rashes with severe in-
flammation based on photographic images (Fig. 4).
4. Clinical Symptoms of Atopic Dermatitis
Clinical symptoms: Clinical symptoms of atopic der-
matitis are divided into 3 age groups: infancy
(younger than 2 years old), childhoodschool-age (2-
12 years old), adolescenceadulthood (13 years and
older).
4.1. Cutaneous Symptoms
The most important cutaneous symptoms for atopic
dermatitis are rashes and itches.
4.1.1. Rash
There is a report on classification of rashes of atopic
dermatitis from 3 perspectives: age groups, morphol-
ogy and distribution, and sites.
(1) Rash morphology: Atopic dermatitis is a cutane-
ous disease that belongs to eczemadermatitis. Pa-
tients with atopic dermatitis under long-term treat-
ment with a topical steroid develop further diverse
symptoms with such side effects as skin atrophy and
telangiectasia. These symptoms will develop into fur-
ther complicated cutaneous symptoms when an infec-
tious disease occurs concurrently.
(2) Characteristics of rashes by age groups
a) Infancy (younger than 2 years old): A rash usu-
ally develops on the cheek, forehead, or the head,
and causes flushing or papules. It will erode and ex-
ude by being scratched and the exudate will form a
crust when it is dried.
b) Childhoodschool-age (2-12 years old): The skin
is apt to develop an atopic condition by gradually
tending to be dried due to degradation of the sebum-
secretion capacity. In addition, the atopic skin may be
repeatedly scratched to develop prurigo nodularis,
erosions, blood crusts, and so on. Rashes most typi-
cally observed in the childhood to the school-age
group include a bend type.
c) Adolescenceadulthood (13 years and older):
This age group is apt to suffer from seborrhea or
acne due to the increase in sebum secretion with
modified rashes. The rash extends from the neck to
the upper chest region and the upper part of back and
spreads like a clothes hanger. Together with the
rashes on the face and the neck, it is distributed like
Katayama I et al.
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Table　1　Defi nition and diagnostic criteria for atopic dermatitis by the Japanese Dermatological Association
Defi nition
Atopic dermatitis is a pruritic, eczematous dermatitis; its symptoms chronically fl uctuate with remissions and relapses.
Most individuals with atopic dermatitis have atopic diathesis.
Atopic diathesis: (i) personal or family history (asthma, allergic rhinitis and/or conjunctivitis, and atopic dermatitis); and/or (ii) pre-
disposition to overproduction of immunoglobulin E (IgE) antibodies.
Diagnostic criteria for atopic dermatitis
1. Pruritus
2. Typical morphology and distribution
1) Eczematous dermatitis
- Acute lesions: erythema, exudation, papules, vesiculopapules, scales, crusts
- Chronic lesions: infi ltrated erythema, lichenifi cation, prurigo, scales, crusts
2) Distribution
- Symmetrical
Predilection sites: forehead, periorbital area, perioral area, lips, periauricular area, neck, joint areas of limbs, trunk
- Age-related characteristics
Infantile phase: starts on the scalp and face, often spreads to the trunk and extremities
Childhood phase: neck, the fl exural surfaces of the arms and legs
Adolescent and adult phase: tendency to be severe on the upper half of body (face, neck, anterior chest and back)
3. Chronic or chronically relapsing course (usually coexistence of old and new lesions)
- More than 2 months in infancy
- More than 6 months in childhood, adolescence, and adulthood
Defi nitive diagnosis of atopic dermatitis requires the presence of all three features without any consideration of severity.
Other cases should be evaluated on the basis of the age and clinical course with the tentative diagnosis of acute or chronic, non-
specifi c eczema.
Differential diagnosis (association may occur)
Contact dermatitis, seborrheic dermatitis, prurigo simplex, scabies, miliaria, ichthyosis, xerotic eczema, hand dermatitis (non-
atopic), cutaneous lymphoma, psoriasis, immune defi ciency diseases, collagen diseases (systemic lupus erythematosus, derma-
tomyositis), Netherton’s syndrome
Diagnostic aids
Family history (bronchial asthma, allergic rhinitis and/or conjunctivitis, atopic dermatitis), personal history (bronchial asthma, al-
lergic rhinitis and/or conjunctivitis), follicular papules (goose-skin), elevated serum IgE level
Clinical types (not applicable to the infantile phase)
Flexural surface type, extensor surface type, dry form in childhood, head/face/neck/upper chest/back type, prurigo type, erythro-
derma type, combinations of various types are common
Signifi cant complications
Ocular complication (cataract and/or retinal detachment): especially in patients with severe facial lesions, Kaposi’s varicelliform
eruption, molluscum contagiosum, impetigo contagiosa
Adapted from reference 1.
a sculptural portrait (portrait type).
(3) Secondary cutaneous changes
a) White dermographism
b) Goosebumps skin
c) Pityriasis alba
d) Pigmentation: This includes postinflammatory
pigmentation, frictional pigmentation, dirty neck, etc.
and is clinically known for orbital darkening and
punctate pigmentation in the lips.
e) Folds: Folds may be seen in from the inner an-
gle to the outer downward of the palpebra inferior
(Dennie-Morgan infraorbital fold), in the neck (ante-
rior neck folds), and in the abdomen. A finding called
palmar hyperlinearity indicates a large number of in-
born palmer folds.
f) Hair loss: Hair loss is seen in the occipital region
for infant patients, in the temporal region for school
age or older patients, and in the eyebrow for adult pa-
tients. Eyebrow hair loss is seen mostly in the outer
half (Hertoghe’s sign).
Atopic Dermatitis
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Table　2　Severity index
There are several criteria proposed for severity assessment of atopic dermatitis at present that require profi ciency in assess-
ment. Accordingly, the following severity levels are defi ned as indices for treatment.
Mild: Only mild rashes are observed irrespective of the area.
Moderate: Rashes with severe infl ammation are observed in less than 10% of the body surface area.
Severe: Rashes with severe infl ammation are observed in ≥10% to <30% of the body surface area.
Most severe: Rashes with severe infl ammation are observed in ≥30% of the body surface area.
Mild rash: Lesions are seen chiefl y with mild erythema, dry skin, or desquamation.
Rashes with severe infl ammation: Lesion with erythema, papule, erosion, infi ltration, lichenifi cation, etc.
Modifi ed from Ministry of Health and Welfare, Japan. [Guidelines for the Treatment of Atopic Dermatitis 2008] (in Japanese).
g) Nail luster: Hard scratching causes pearl-like
luster of nails (pearly nail).
h) Diffuse flushing of the facial surface: The face
may acutely flush over the entire surface. It is likely
caused by sustained inflammation and scratching.
4.1.2. Itch
Itch is caused by increase in skin temperature result-
ing from bathing, exercise, sleep, ointment applica-
tion, etc., sweating due to irritation and body warmth
(itch when sweating), and perspiration stimulation. It
also occurs when woolen clothes contact the skin
(wool intolerance).
(1) Control of itch: In early infancy, the negative
impact of scratching can be weakened by covering
the scratched site with bandages, clothing, etc., or by
wearing gloves. It is not until adolescence that one
understands that scratching will aggravate the cuta-
neous symptoms and comes to restrain oneself from
scratching.
(2) Sleep disorders: Sleep disorders include diffi-
culty in falling asleep and awakening during the
night. The difficulty in falling asleep is caused by a
strong sensitivity to itch due to body warmth while
sleeping.
(3) Scratch addiction: While scratching during the
nighttime is an unconscious reflex movement,
scratching during the daytime involves a conscious
element. It is reportedly a scratching phenomenon
that is performed unintentionally but preferably
(scratch addiction).21
4.2. Symptoms Other than Cutaneous Symptoms
4.2.1. Symptomsfindings incidental to rashes
Dermatopathic lymphadenopathy occurs when a cu-
taneous symptom with certain severity and spread
may cause swelling of regional superficial lymph
nodes. It is indolent and not indicative of infection.
4.2.2. Symptoms in other organs
(1) Cataract: Cortical cataract with an anterior sub-
capsular or posterior subcapsular opacity may pro-
gress to cover all layers. With a gender ratio of ap-
proximately 1:2, it occurs most frequently in individu-
als 15-24 years of age, with a severe form of rash on
the facial surface in particular. The frequencies of
complications with cataracts are reported to be 2.0%
of all patients and 5.5% of severe patients.
(2) Retinal detachment: The retinal detachment ac-
companying atopic dermatitis is reported to occur
with a hiatus caused by continuous external forces
applied to the eyeball. It occurs predominantly be-
tween the ages of 16 to 25 and frequently among pa-
tients who strongly rub their eyelids or who pat their
own faces. The frequencies of complications with reti-
nal detachment are reported to be 0.5% of all patients
and 2% of severe patients.
(3) Airway hyperresponsiveness: A study on airway
hyperresponsiveness caused by histamine inhalation
load in children with atopic dermatitis found that pa-
tients with atopic dermatitis not complicated with
asthma showed significantly worse airway hyperre-
sponsiveness compared with healthy controls.
(4) Mental symptoms: Atopic dermatitis may cause
symptoms such as social withdrawal resulting from
disappointment with existing therapies, discontent
with responses of doctors, disappointment with the
probability of cure, and so on. Severe atopic dermati-
tis cases may be accompanied by psychosomatic
problems.
(5) Neurological symptoms: Paresthesia may occur
in the distal extremities with aggravation of dermati-
tis symptoms and lesional atopic myelitis cervicalis
may be observed in the cervical region in MRI.
(6) Intestinal tract symptoms: Severe cases may be
accompanied by such symptoms as diarrhea and con-
stipation.
5. Investigation of Causes and Exacerbat-
ing Factors for Atopic Dermatitis and
Countermeasures
Given that causes and exacerbating factors may vary
according to age, individual differences of patients,
environment, and lifestyle, it is important to take
countermeasures in consideration of the conditions of
the individual patients.
5.1. Foods
Food allergens are investigated by performing de-
tailed history taking, allergen tests and then by com-
Katayama I et al.
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Fig.　4　Examples of mild rashes and rashes with severe infl ammation of atopic dermatitis. Examples of 
mild rashes includes (A) Face: Mild desquamation, erythema, (B) Body trunk: mild desquamation, dry 
skin, (C) Lower limb: Mild desquamation, erythema, including partial mild lichenifi cation. Examples of 
rashes with severe infl ammation includes (D) Face: Apparent erythema, desquamation, apparent infi ltra-
tion, (E) Body trunk: Apparent erythema and lichenifi cation, (F) Lower limb: Apparent erythema, papule, 
scratch mark, lichenifi cation.
A D
B E
C F
bining elimination tests and provocation tests (not
performed for cases accompanied by anaphylaxis) for
suspicious allergens detected to remove the deter-
mined allergens. Countermeasures are taken by nu-
tritional care introducing alternative foods introduced
and providing guidance to the family without ran-
Atopic Dermatitis
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domly removing allergens.
5.2. Sweating
Sweating is an important cause and exacerbating fac-
tor for atopic dermatitis, hence washing away sweat
by bathing and showering will lead to the improve-
ment of symptoms. Bathing and showering are im-
portant not only for washing away the components of
perspiration but also for washing away allergens,
such as dust and pollens, and microbes on the skin
surface.
5.3. Physical Irritation
Causes and exacerbating factors other than the
above-mentioned perspiration include clothes, dry
air, hairs, and cosmetics for adult patients. Cosmet-
ics, shampoo, and soaps need to be selected appropri-
ately, exchanging products that cause symptoms.
5.4. Environmental Factors
Allergens such as mites and house dust, pollen aller-
gens in specific seasons, and organic solvents such as
formaldehyde and toluene can become problematic.
Being sensitized to mites in infancy is reportedly a
marker for the development of asthma.22 Periocular
pathological changes are often observed during air-
borne pollen seasons.23
5.5. MicrobesFungi
If no infectious symptoms are seen in the affected
part, a topical steroid can be applied to encourage the
improvement of the cutaneous symptom, even if the
site is densely populated with Staphylococcus aureus
(with bacterial counts of 1000 cfu10 cm2 or more as
detected by the stamp method).
(1) An antimicrobial therapy should be performed
if any infectious symptoms are observed.
(2) Care should be taken against microbial substi-
tution with methicillin-resistant Staphylococcus aureus
(MRSA).
(3) The skin should be kept clean by frequent bath-
ing or showering, etc.
(4) Disinfectants such as povidone-iodine solution
should not be applied.
5.6. Contact Antigen
Contact dermatitis is divided into allergic contact der-
matitis, which is developed by a sensitized patient,
and primary irritant contact dermatitis, which can be
developed by anyone depending on the antigen level.
5.7. Stress
Aggravation by mental stress is often experienced in
daily medical practice. The high rate of aggravation of
atopic dermatitis reported in areas affected by the
Great Hanshin-Awaji Earthquake definitely proves
the correlation between stress and atopic dermati-
tis.24
5.8. Scratching
Scratching will not only damage the cutaneous bar-
rier functions by injuring the skin, but also worsen
the symptoms by causing the release of various phlo-
gogenic agents.
5.9. Perinatal Prevention
A randomized comparative study that assessed
whether consumption of an elimination diet free of
highly sensitized food antigens such as eggs and
cow’s milk by pregnant or lactating mothers can pre-
vent newborns from developing sensitization to food
allergens or atopic dermatitis revealed that elimina-
tion of eggs or cow’s milk has no preventive effect.25
A case-series study in high-risk children was con-
ducted to determine whether moisturizer application
during the newborn period prevents the development
of atopic dermatitis, in light of the importance of cuta-
neous barrier functions in atopic dermatitis. The re-
sults showed that the subject group, in which mois-
turizer was applied during the newborn period, had a
low incidence rate of 15%.26 However, the effect of
moisturizer application during the newborn period
needs to be demonstrated in a randomized compara-
tive study in future.
5.10. Others
The pathology of atopic dermatitis is a chronic inflam-
mation of the skin that is aggravated by the deteriora-
tion of compliance. It is necessary to educate patients
repeatedly so they may understand the pathology and
realize that a long-term antiinflammatory therapy is
required.
6. Summary of the Basic Therapy of Atopic
Dermatitis
6.1. Basics of Treatment
Because the treatment of atopic dermatitis requires
appropriate diagnosis and evaluation of cutaneous
symptoms, the basics of treatment under this guide-
line include 3 mainstays. These are investigation and
countermeasures of causes and exacerbating factors;
second, correction of skin dysfunctions (skin care);
and third, pharmacotherapy. These are based on the
concept that this disease is an inflammatory cutane-
ous disease that forms an eczematous lesion against a
backdrop of atopic diathesis, with numerous factors
involved in the occurrence and aggravation and aber-
rant function in the skin (Fig. 5). These 3 points are
equally important and thus need to be appropriately
combined in accordance with the symptoms of each
patient.
(1) Investigation and countermeasures of causes
and exacerbating factors: Because the importance of
the individual factors depends on the individual pa-
tients, it is important to investigate fully the factors
through diagnosis, and to take reasonable and appro-
priate countermeasures.
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Fig.　5　Important points of these guidelines. Modifi ed from Ministry of Health and Wel-
fare, Japan. [Guidelines for the Treatment of Atopic Dermatitis 2008] (in Japanese).
2. Assessment of cutaneous symptoms
In selecting a therapy, cutaneous symptoms need to be properly assessed.
3. Basics of treatment
Based on the above assessment, investigation/countermeasures against 
causes and exacerbating factors, skin care, and pharmacotherapy should be 
implemented by being optimally combined for each patient. Sufficient 
information about the treatment should be transmitted to the patient to build a 
favorable partnership.
1. Diagnosis
Appropriate diagnosis should be ensured by discriminating them from other
diseases with similar symptoms, such as eczema and dermatitis, in accordance 
with the abovementioned concept.
Outline of the guidelines for therapy
Pharmacotherapy
Diagnosis
Severity assessment
Investigation/countermeas-
ures against causes and
exacerbating factors
Skin care
(correction of abnormal 
cutaneous functions)
(2) Skin care (correction of abnormal cutaneous
functions): The skin barrier functions of patients with
atopic dermatitis are deteriorated due to abnormality
in function such as deteriorated water retentivity, low-
ered threshold of itch, and susceptibility to infection.
Correcting those abnormalities (skin care) is ex-
tremely important in treatment, chiefly by good hy-
giene and moisture retention of the skin.
(3) Basics of pharmacotherapy: If countermeasures
against the causes and exacerbating factors and the
skin care have not resulted in improvement of derma-
titis, pharmacotherapy will be needed.
a) Final objective: The final objective of treatment
is to achieve a level with no or mild symptoms, if any,
which should not interfere with daily life and require
minimal pharmacotherapy.
b) Assessment of severity and activity level: At-
tempts have been made to assess the severity and ac-
tivity level by using the IgE level, eosinophilic leuko-
cyte count, LDH level, TARC level, and VAS itch
score.
c) Remission-induction therapy: To maximize the
therapeutic effect, in particular the pharmacothera-
peutic effect, and to minimize the side effects, the pa-
tient should be follow up every 1 or 2 weeks to evalu-
ate and verify the effects and change the therapeutic
agents and method as needed. If no improvement is
observed or if an abnormal change in symptoms is
observed after approximately 1 month of remission-
induction therapy, referral of the patient to a more
specialized medical institution should be considered.
d) Remission maintenance therapy: If symptoms
cannot be controlled or if symptoms frequently re-
lapse after completion of remission induction, therapy
should be changed to remission maintenance ther-
apy. Remission maintenance therapy is mainly based
on the external application of tacrolimus. If remission
cannot be maintained after approximately 6 months,
the patient should be referred to a specialized medi-
cal institution to define the condition as severe, most
severe, or intractable, in consideration of prolonged
use of topical tacrolimus.
e) Severe, most severe, or intractable conditions
(cases where remission maintenance therapy is diffi-
cult to execute): If remission cannot be maintained,
external application of a higher ranked steroid, oral
administration of immunosuppressive agents (cy-
closporine), oral administration of steroids, ultraviolet
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light therapy, or psychosomatic medical therapy
should be used.
Hospital treatment is effective for severe, most se-
vere, and intractable cases. Education should be pro-
vided to such patients on environmental factors, life-
style, dietary habits, personal hygiene management,
and correction of psychological problems, during
hospitalization.
Oral administration of steroids should not be exe-
cuted in principle. However, if the patient develops
extremely severe symptoms that cannot be controlled
with external medication, such oral administration
may be used for a short period of time.
f) Precautions during treatment: Given that the du-
ration of illness is often prolonged, its association
with growth in children and with lifestyle related dis-
eases, vitamin D deficiency, and ophthalmologic
problems in adults should be considered.
6.2. Precautions During Treatment
If an abnormal change is observed in symptoms dur-
ing treatment or if no improvement is observed after
treatment based on a basic therapy for approximately
one month, referral to a more specialized medical in-
stitution should be considered. Hospital treatment is
effective for patients with severe or most severe
cases.
7. Skin Care Against Atopic Dermatitis
Skin care is highly important, as is shown by consid-
eration of the fact that the skin tends to become more
prone to drying due to aging, and given the adverse
effects of settlement of Staphylococcus aureus on the
skin on the aggravation of symptoms.
7.1. Dry Skin
The skin of patients with atopic dermatitis is gener-
ally in a dried condition, not only in the lesion but
also in an apparently normal area, due to insensible
water loss (transepidermal water loss; TWL). In such
conditions, with facilitation of transcutaneous inva-
sion of allergens and irritants, likely resulting in aller-
gic reactions and irritability, patients may come to
suffer from itch due to the lowered threshold of itch.
Abnormality in the water barrier function and the
water retention capability of the horny cell layer are
considered as causingexacerbating factors of atopic
dermatitis. Accordingly, the incidence rate of atopic
dermatitis could be decreased by moisturizer applica-
tion during the newborn period.
7.2. Staphylococcus Aureus Flora
If the bacterial count is small (in the case of a bacte-
rial count of 1000 cfu10 cm2 or less by the stamp
method), dry skin symptoms will be improved only
by continuous use of a moisturizer. If the bacterial
count is larger, it is important to take a skin care regi-
men with consideration of the bacterial flora on the
skin surface.
7.3. Important Points in Skin Care
(1) Skin care against dry skin: Hydrophilic oint-
ments and water absorptive ointment with high mois-
ture retention include urea preparations, heparinoid
preparations, water-soluble collagen preparations, so-
dium lactate preparations, and elastin hydrolysis
preparations.
(2) Skin care against injured skin: An oleaginous
ointment (ointment in a narrow sense) with skin pro-
tective action should be externally applied. Given that
a moisturizer is known to exert a higher moisturizing
effect when externally applied twice a day than when
applied once a day, consideration should be given to
the number of external applications.27
(3) Good hygiene of the skin and skin care: To en-
sure healthy skin, bathing and showering should be
strictly observed with appropriate moisturizer or skin
protectant applied externally as needed.
(4) Practical home skin care
a) Bathing: Although moisturizer application is rec-
ommended immediately after bathing, reports have
shown that the moisturizing effect is not influenced
by a time lapse after bathing. Therefore, physicians
should instruct patients not to forget the external ap-
plication of moisturizers.28
b) Shower: Sweating is considered as an exacerbat-
ing factor for atopic dermatitis. In the sweaty summer
season, washing away sweat by showering improves
rashes.29
c) Shampoo: Given that shampoo and soap residue
may aggravate rashes, soap and shampoo should not
be left in such regions as the hairline, the side of the
nose, and jaws, etc.
8. Pharmacotherapies for Atopic Dermati-
tis
8.1. External Medicine
8.1.1. Topical therapy
Topical therapy refers to skin care chiefly with mois-
turizers, and to inflammation control chiefly with topi-
cal steroids and tacrolimus ointments (immunosup-
pressive ointment, topical calcineurin inhibitor).
Although basic therapy for controlling inflamma-
tion in the acute phase consists of topical steroids,
the use of tacrolimus ointment or topical steroids in-
termittently in combination with a moisturizer is use-
ful in the remission maintenance period. This therapy
is referred to as proactive therapy (Fig. 6) as opposed
to reactive therapy (Fig. 7), in which topical therapy
is administered only when the rash worsens. Proac-
tive therapy has been shown to not only control the
relapse of cutaneous symptoms, but also to be cost-
effective.30 The use of a medical dressing or Tubifast
(Allergy Health Care, Nara, Japan) with an externally
applied medicine is effective for the prevention of
scratching.
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Fig.　6　Proactive therapy for atopic dermatitis.
† Topical steroid/topical tacrolimus.
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Firmly apply an external medicine at an optimum dose† + moisturizer.
Apply the medicine thinly over the entire site of rash development 
even if the symptoms are mild at least thrice, twice, or once per week.† 
Thrice 
a week
Twice 
a week
Once 
a week
Twice 
a week
Once 
a week
Apply a moisturizer all over the body daily.
Fig.　7　Reactive therapy for atopic dermatitis.
† Topical steroid/topical tacrolimus.
Apply a moisturizer all over the body daily.
Apply an external medicine† repeatedly once a day to the site 
where an itch occurred during the day.
The remission period will increase progressively.
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Firmly apply an external medicine at an optimum dose† + moisturizer.
8.1.2. Moisturizer
Although the use of an ointment-based drug product
with high moisture retaining properties is recom-
mended for the treatment of mild cases with the aim
of moistening and protecting the skin, recovering and
maintaining the barrier function, the drug product
should be selected in consideration of the outdoor air
temperature, humidity, and usability. For the treat-
ment of weeping lesions in the acute phase, a surface
dressing with a zinc ointment may be effective. Urea
preparations should be used with caution, as they can
stimulate an eroded surface or strongly inflammatory
skin. A moisturizer can also cause contact dermatitis.
The use of a moisturizer is useful to prevent relapse
of atopic dermatitis; however, studies have shown
that the continuous use of a moisturizer since the
newborn period may reduce the incidence rate or de-
lay the development of atopic dermatitis.31,26
8.1.3. Pharmacologyaction mechanism of the
steroid drug
Upon entering a cell, steroids bind receptors that
form complexes with heat shock protein (HSP90),
which is found in the cytoplasm, and migrate with the
complex into the nucleus. There they activate steroid-
responsive genes to exert their pharmacological ac-
tions that include antiinflammatory action in a narrow
sense, antiallergic action, and immunosuppressive ac-
tion.32
8.1.4. Administration method of topical steroids
(1) Selection of topical steroid: Topical steroids are
classified into 5 ranks from weak to strongest. A ster-
oid of an appropriate rank should be used in accor-
dance with the severity of cutaneous symptom33 (Fig.
8).
(2) Points to note in external application of steroid:
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Fig.　8　Administration method of topical steroid against atopic dermatitis.
†This medicine should be applied to an inpatient in liaison with specialist doctors. 
‡Indicated for patients with most severe symptoms aged 16 years old or older. To be discontinued within 3 
months.
§This medicine should be applied in accordance with the package insert instructions.
2 to 12 
years old
Younger than 
2 years old
13 years old 
or older
Only mild rashes 
are observed 
irrespective of the area
Rashes with severe 
inflammation: less than 10% 
of the body surface area
If efficacy is insufficient (step-up)
If efficacy is sufficient (step-down)
Topical steroid 
(mild or lower)
Oral corticosteroid 
(temporarily as needed)†
Cyclosporine 
(Neoral®)‡,§
Index of dose of 
ointment (5 g tube)
Very small amount 0.5 units or less (2.5 g) 
5 FTU
0.5 to 1.5 units (7.5 g) 
15 FTU
1.5 to 5 units (25 g) 
50 FTU
Antihistaminics, antiallergics, herbal medicine (as needed)
Moisturizer/protectant (applicable to mild to most severe cases)
Oral 
medicine
Topical steroid 
(strong or lower)
Mild Moderate Most severeSevere
All age groups
Topical steroid 
as needed 
(mild or lower)
Tacrolimus (0.03%) (13 to 15 years old)§, to sites where the use of steroids is not appropriate
Tacrolimus (0.1%) (16 years old or older)§, to sites where the use of steroids is not appropriate
Tacrolimus (0.03%) (2 to 12 years old)§, to sites where the use of steroids is not appropriate
Topical steroid 
(strong or lower)
Topical steroid 
(very strong or lower)
Topical steroid 
(very strong or lower)
Topical steroid 
(very strong or lower)
Topical steroid 
(very strong or lower)
Topical steroid 
(very strong or lower)
Topical steroid 
(strong or lower)
Basic examples of pharmacotherapy
Rashes with severe 
inflammation: 10% or more 
to less than 30% 
of the body surface area
Rashes with severe  
inflammation: 30% or more of 
the body surface area
Temporary hospitalization is
 recommended, in principle
A topical steroid to be applied to atopic dermatitis
must be selected in accordance with the severity and
the site of symptoms and the age of the patient.
a) Application to the facial surface and points to
note: A topical steroid should be applied carefully to
the facial surface, neck, etc., which have an active
percutaneous absorption. When it is applied to such
sites, the administration should be limited to the
shortest period possible in consideration of progres-
sive reduction, intermittent administration, and a
change to tacrolimus ointment as soon as possible.
b) Topical steroids and side effects: Patients should
be evaluated for severity of their condition approxi-
mately 1-2 weeks after the start of treatment with a
topical steroid to identify any side effects and the
need for stepping down or stepping up the dose. The
absorption ratio of steroids varies significantly among
skin sites. In children and the elderly with deterio-
rated cutaneous barrier functions and in summer
when there is a higher sweat volume, the absorption
ratio changes. Well-known side effects of steroid di-
rectly affecting the skin are shown in Table 3. If side
effects are seen during treatment with topical ster-
oids, the therapy should be shifted to a tacrolimus
ointment while gradually stepping down the dose.
c) Monitoring of the dose of topical steroid: Moni-
toring should be performed twice daily (morning,
evening, and after bathing). Improvement in symp-
toms should be evaluated with the goal of gradual
progressive reduction to change the therapy to a topi-
cal nonsteroidal agent, while ensuring the absence of
relapse after once a day to alternate-day administra-
tion. The finger-tip unit (FTU) will be used as an in-
dex of external dose.34 One FTU is a quantity of oint-
ment that will be pushed out of a tube of 5 mm in di-
ameter onto the distal end on the pulp side of an
adult’s forefinger and is equivalent to approximately
0.5 g. One FTU can cover two palms of an adult (2% of
the body surface area) (Fig. 9). The dose required to
cover the whole body is 50 FTU or 25 g. A dose for
children is also proposed.35
It has been reported that a topical steroid of the
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Fig.　9　Index of external dose of topical steroid: fi nger tip unit (FTU). 1 FTU is the 
quantity of ointment that will be pushed out of a tube of 5 mm in diameter onto the 
region from the DIP joint to the distal end on the pulp side of an adult’s forefi nger 
and is equivalent to approximately 0.5 g. 1 FTU can cover 2 palms of an adult. 
Modifi ed from Ministry of Health and Welfare, Japan. [Guidelines for the Treatment 
of Atopic Dermatitis 2008] (in Japanese).
Table　3　Side effects of topical steroid in the skin or affected part
 1. Acne-like rash, including folliculitis and rosacea
 2. Eyelid and perioral dermatitides
 3. Epidermal-dermal atrophy, dermal vulnerability (most likely to occur on the geriatric or sunlight damaged skin, intertriginous 
zone, or facial surface)
 4. Delay in wound healing
 5. Gluteal granuloma
 6. Purpura
 7. Telangiectasia and erythema
 8. Skin striae
 9. Depigmentation
10. Hypertrichosis
11. Hidden or exacerbated dermatophyte infection
12. Secondary infection or exacerbation of existing infection
13. Contact dermatitis
(i)  May be caused by an ingredient of the preservative or other base material.
(ii) May be caused by a corticosteroid molecule. In this case, the skin may cross-react with a corticosteroid molecule of simi-
lar structure.
14. Others
Adapted from Drake LA, et al. J Am Acad Dermatol 1996;35:615-9.
strong class or higher shows no difference in efficacy
after 3 weeks or more between twice-a-day external
application and once-a-day external application. It is
recommended that a strong topical steroid be initially
applied twice a day and then changed to once-a-day
application after remission of an acute or intractable
lesion is observed, for the purpose of enhancing the
compliance of the patient, reducing side effects, and
reducing medical expenses.36
d) Response to exacerbation due to discontinuation
of long-term application of a topical steroid: Patient
should be advised against discontinuing the use of
the drug on his own judgment. In addition, sufficient
explanation should be provided to the patient about
the side effects likely to be caused by the topical ster-
oid and that the side effects can be avoided by evalu-
ating cutaneous symptoms and monitoring drug con-
sumption.37
e) Measures against acute exacerbation: In the
event of acute exacerbation of a cutaneous symptom
due to a change of treatment on the patient’s own
judgment, etc., a topical steroid should be adminis-
tered at a necessary and sufficient dose. If systemic
aggravation is observed, the patient should be hospi-
talized for a short period and a steroid systemically
administered as needed.
f) Precautions in external application of steroid in
children: It should be emphasized in children as well
that antiinflammatory therapy plays a central role in
pharmacotherapy chiefly with a topical steroid. Ad-
ministration methods for children are divided into the
age groups of <2 years of age, 2-12 years of age, and
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>13 years of age. Care should be taken so that insuffi-
cient administration for fear of side effects likely gen-
erated in the treatment of children may not result in
prolonged symptoms.
(3) Selection of external medicine according to
symptoms: In principle, in the treatment of atopic der-
matitis, a moisturizer or skin care product should be
applied to a mild eczematous lesion or dry skin on
the facial surface without applying any topical ster-
oids. It is reported that twice-a-day external applica-
tion of a moisturizer (preparation containing hepari-
noid) significantly inhibits the relapse of inflamma-
tion of atopic dermatitis compared with the untreated
group (no application group).
8.1.5. Topical immunosuppressant (tacrolimus
ointment [ProtopicⓇ])
(1) Pharmaceutical form and mechanism of action
of tacrolimus ointments: Tacrolimus ointments will
be used when existing therapies are not effective
enough or not indicated because of side effects. It
should be used in consideration of precautions and af-
ter obtaining informed consent from the patients.
Tacrolimus ointments (trade name: protopic oint-
ment) are available in 2 dose forms: ointment 0.1% ap-
plicable to patients 16 years of age or older and oint-
ment 0.03% applicable for children aged 2-15 years.
The action mechanism of tacrolimus is the inhibition
of the function of T lymphocytes, which play a central
role in the development of allergic inflammation, and
improvement in the barrier function. Although
tacrolimus ointments have a similar beneficial effect
as that of strong steroids, their absorption from nor-
mal skin is lower than that of steroids because of
their higher molecular weight. This property is con-
sidered an advantage because they are more absorp-
tive and effective for the treatment of lesions with
acute dermatitis associated with compromised cuta-
neous barrier function, whereas they become less ab-
sorptive and less likely to show side effects as derma-
titis subsides.
(2) Instructions for the use of tacrolimus oint-
ments: The tacrolimus ointment is usually applied ex-
ternally once a day after bathing. Excessive exposure
to ultraviolet light should be avoided when the oint-
ment is applied externally. A 0.1% tacrolimus oint-
ment for adults should be administered at a dose of
5 g or less. A 0.03% tacrolimus ointment for children
aged 2 to 5 years (<20 kg in body weight) should be
administered at a dose of1 g; for children aged 6 to
12 years (20-50 kg in body weight), at a dose of 2-4 g;
and for children 13 years or older (50 kg in body
weight), at a dose of 5 g. The tacrolimus ointment
should be administered at a maximum of twice per
day. When applied twice per day, an interval of ap-
proximately 12 hours between applications is recom-
mended. Occlusive dressing therapy should not be
used because it may cause an increase in the blood
level. Continuous external application of a tacrolimus
ointment two to three times per week after remission
induction can significantly inhibit the relapse of
symptoms (proactive therapy).38-40
(3) Side effects of tacrolimus ointments: No severe
systematic adverse events were observed in a study
of post-marketing prolonged administration; there-
fore, tacrolimus ointments are considered safe. Pre-
cautions for the use of tacrolimus ointment include
the possibility of skin effects such as a burning sensa-
tion at the start of external application and the poten-
tial aggravation of local infectious disease in the skin.
Although the stimulatory effects of the ointment on
the skin will most likely disappear after several days,
a tacrolimus ointment can become intolerable be-
cause of the burning sensation. This problem can be
managed by using a moisturizer before the applica-
tion of the ointment or by using a tacrolimus oint-
ment in combination with a topical steroid for a short
period of time. Combinations with other external
medicines should be avoided because of potential ef-
fects on the stability and absorptive properties of the
tacrolimus ointment. Tacrolimus ointments should
not be used on rashes associated with infectious dis-
eases of the skin. Tacrolimus ointments cannot be ap-
plied to an eroded surface or the surface of an ulcer
because of its stimulatory effects and absorption. A
tacrolimus ointment cannot be applied to patients
with ichthyosiform erythroderma (such as Nether-
ton’s syndrome), whose blood tacrolimus level can in-
crease because of elevated percutaneous absorption
and because it can cause side effects such as nephro-
pathy. In addition, tacrolimus ointments cannot be ap-
plied for reasons of safety to patients with nephropa-
thy, pregnant women, infants younger than 2 years of
age (at this point in time), and patients receiving pho-
totherapy. Regarding the risk of lymphoma and skin
cancer, it has been reported that the external applica-
tion of tacrolimus ointment will not lead to an in-
crease in the incidence rate of these diseases.41-44
8.1.6. Topical non-steroidal antiinflammatory dr-
ugs
No data definitely shows that nonsteroidal antiinflam-
matory drugs (NSAIDs) are effective for eczematous
lesions of atopic dermatitis. There is no description of
NSAIDs in the guidelines for the treatment of atopic
dermatitis of the United States or Europe.45
8.2. Oral Medicine
8.2.1. Antihistaminicsantiallergics
(1) Pharmacological actionsaction mechanism
a) Antihistamines: The main pharmacological ac-
tion of antihistamines is to antagonize histamine in
the histamine H1 receptor in tissues to inhibit its ac-
tion. In recent years, a new concept of inverse ago-
nism has been advocated for the H1 receptor.46 The
inverse agonist (H1 receptor antagonist) combines
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with the inactive receptor to shift the equilibrium of
the receptor towards the inactive state in addition to
acting as a competitive inhibitor of the agonist.
b) Antiallergics: Antiallergics are divided into me-
diator antireleasers, which are antiallergics in a nar-
row sense, thromboxane A2 inhibitors, leukotriene
receptor antagonists, and cytokine inhibitors, as well
as classic antihistamines.
(2) Administration method: Since differences in ef-
ficacy are found amongst individual patients in daily
medical care, it is necessary to explore and replace
drugs that are not effective after 2 weeks of admini-
stration with another drug appropriate for the individ-
ual patient.
a) Treatment of itch: Since itch is normally caused
by irritation of the end of C nerve fiber located at the
epidermal-dermal junction. The histamine H1 recep-
tor is located at the C fiber, and antihistaminics and
antiallergics with antihistaminic action are expected
to inhibit itch.
b) Evidence of efficacy of antihistaminics: Hoare et
al. reported that oral antihistaminics lack grounds for
efficacy after their evidence-based analysis of ran-
domized studies on the efficacy of treatments for
atopic dermatitis extracted from various databases.47
Recently, however, a large-scale clinical study was
conducted with fexofenadine hydrochloride that
showed its usefulness in a randomized, double-blind,
parallel-group comparative study.48
(3) Side effects
a) Central nervous system effect: The drug gener-
ally generates side effects in the form of sleepiness,
loss of concentration, or malaise, and it may cause ex-
citement if administered in a large quantity. Precau-
tion is necessary in use of antihistaminics in children,
particularly against convulsion. A second-generation
antihistaminics is characterized by reduced sleepi-
ness and central nervous system effects because it
has more difficulty in passing through the blood-
brain barrier. In evaluating sedation, sleepiness
should be differentiated from impaired performance
(a condition with deteriorated operating efficiency).49
b) Anticholinergic action: The anticholinergic ac-
tion may cause dry mouth, sense of mucosal dryness,
urinary retention, and so on. This drug is contraindi-
cated for patients with glaucoma or lower urinary
tract obstructive disease (prostatomegaly, etc.).
c) Digestive symptoms: These include nausea,
vomiting, diarrhea, and abdominal pain.
d) Teratogenicity: An antihistaminics generally
passes through the placenta and through the blood-
brain barrier of the fetus. Antihistaminics known to
be safe to pregnant women are chlorpheniramine and
clemastine, and these are first-line drugs for pregnant
patients. Most antiallergics are relatively new and
thus their safety for pregnant women is not well
known. Accordingly, the aforementioned antihista-
minics should be selected as needed.
e) Application to patients with hepatic dysfunction:
Antiallergics are mostly metabolized in the liver and
excreted into the urine. However, the frequency of
the occurrence of drug induced hepatopathy due to
antiallergics is low.
f) Application to patients with renal dysfunction:
For drugs excreted through the kidney as the main
excretion pathway (ketotifen fumarate, cetirizine hy-
drochloride, epinastine hydrochloride, oxatomide, be-
potastine besilate, tranilast, etc.), decreased renal
function may inhibit the excretion of the drug, result-
ing in a rise in blood levels of that drug. In that case,
use of drugs that are decomposed chiefly in the liver
(azelastine hydrochloride, ebastine, emedastine difu-
marate, etc.) or excreted into feces (fexofenadine hy-
drochloride) is recommended.
g) Drug interactions: A general drug interaction of
an antihistaminics is caused by concomitant use with
other central depressants. Concomitant use of the
drug with alcohol, hypnotic, or psychotropic drugs
and so on, may cause massive sedation, vertigo, mal-
aise, weakness etc. Concomitant use with tricyclic an-
tidepressants or anticholinergics may cause dry
mouth, intestinal obstruction, aggravated glaucoma,
memory disorder, etc.. Concomitant use with a
monoamine oxidase (MAO) inhibitor may cause
headache, arrhythmia, hypertension, etc. because of
the strengthened action of catecholamine. Few antial-
lergics have similar interactions as are seen in anti-
histaminics.
8.2.2. Other oral medicines
(1) Oral steroid: Because the oral administration of
a steroid has various severe side effects, long-term
administration of the agent should be avoided. In
general, prednisolone should be administered to an
adult patient at a dose of 10-15 mgday in combina-
tion with antihistaminics or antiallergics and discon-
tinued within as few days as possible. The use of
these drugs in children with atopic dermatitis is not
recommended in consideration of the side effects.
(2) Immunosuppressant: Cyclosporine (NeoralⓇ)
was added to the list of treatments of atopic dermati-
tis in October 2008, in Japan. Cyclosporine is newly
applicable to patients aged 16 years or older with re-
sistance to existing therapies, subject to a washout
within 3 months of administration, as required by the
administration guidelines. The drug will be usually
administered twice a day at a daily dose of 3-5 mg
kgday. If a problematic side effect is reported or if a
side effect does not improve by dose reduction, ad-
ministration should be discontinued. The duration of
administration should be minimized as much as pos-
sible. If the side effect does not improve after 8 weeks
of treatment, the administration of this drug should
be discontinued. Even if the drug shows efficacy, one
treatment period should be limited to 12 weeks or
less. If the drug will be re-administered, a washout
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period of 2 weeks or longer is necessary. The pa-
tients need to be periodically inspected for several
side effects, similar to cases of psoriasis vulgaris
(e.g., renal function test, hypertension measurement,
and blood cyclosporine level measurement [trough
value]).50
9. Adjunctive Therapies Other than the Ba-
sic Therapy of Atopic Dermatitis
This section introduces adjunctive therapies other
than the basic therapy with relatively firm evidence.
9.1. Ultraviolet Light Therapy
Ultraviolet light therapy has been shown to be useful
in patients with severe, most severe, or intractable
conditions who do not show significant improvement
after the administration of topical moisturizers, the
provision of appropriate patient education, remission
induction therapy, and remission maintenance ther-
apy based on a reliable diagnosis.51 Narrow-band
UVB (NB-UVB) therapy is used. UVA1 is also effec-
tive in the acute exacerbation phase. In addition to
topical PUVA therapy, bath-PUVA therapy and oral
PUVA therapy are also available. Further, a 308-nm
Excimer laser is also available. Ultraviolet light ther-
apy and photochemotherapy are associated with a
risk of skin cancer as a side effect.52 Therefore, they
should not be applied to underage patients or patients
receiving tacrolimus ointment therapy or oral CYA
therapy.
9.2. Herbal Medicines
Those herbal medicines covered by the health insur-
ance system and medicines with safety proven in con-
trolled studies, such as Hochuekkito are used.
Jumihaidokuto, Shofusan, Saikoseikanto, and Ho-
chuekkito are Chinese medicine prescriptions that
contain a licorice that may cause pseudoaldostero-
nism or myopathy. Hochuekkito is reported to cause
interstitial pneumonitis, hepatic dysfunction, and
jaundice and thus requires due caution in use.53
9.3. n-3 Polyunsaturated Fatty Acid
This therapy should be applied when a rise in the n-
6n-3 ratio is observed in measurements of blood un-
saturated fatty acid levels. Adoption of this therapy
should be consideration when both poor intake of the
n-3 polyunsaturated fatty acids and excessive intake
of n-6 polyunsaturated fatty acids are confirmed with
a rise in the n-6n-3 ratio observed in a review of the
menu of meals (food diary) conducted together with
a nutritionist.
9.4. Psychosomatic Approach
Counseling will be given by the attending physician
or, as appropriate, by a psychosomatic physician, psy-
chiatrist, or psychotherapist. For general physicians
not specialized in psychosomatic medicine, treatment
by antianxiety agents, antidepressant, or hypnotic is
recommended instead of a psychotropic agent for
pharmacotherapy.
9.5. Alternative Therapy
Many reports are published on the efficacy of acu-
puncture and moxibustion in journals of Eastern
medicine. Balneotherapy, aromatherapy, herb ther-
apy are also reported to be effective. However, since
many of them lack scientific verification and such
therapies may cause aggravation of cases, they
should be performed under the supervision of a phy-
sician. Probiotics are evaluated as having prophylac-
tic effects when administered to the mother and child
and reportedly expected to improve rashes with
slight adjunctive therapeutic effects to children.
10. Points of Referral to a Specialist
In the treatment of atopic dermatitis, if the rash does
not improve after approximately 1 month of treatment
in accordance with the guidelines, as we discuss
later, referral of the patient to a specialist or special
institution should be considered. Caution should be
exercised when complications are observed or when
the patient is a child.
10.1. Complications and Countermeasures
(1) Allergic diseases: Allergic diseases such as
asthma and allergic rhinitisconjunctivitis are the
most frequent complications.
(2) Cutaneous infectious diseases: The causative
microorganisms for impetigo contagiosa are Staphy-
lococcus aureus and Streptococcus hemolyticus. Le-
sions should be kept clean by regular showering and
then covered with clean gauze so that it cannot be
scratched. For expanding rashes, antimicrobials
should be administered to the whole body. Kaposi
varicelliform eruption indicates a condition with a
wide area of the body being percutaneously infected
with herpes simplex virus. For treatment, an anti-
herpesvirus agent will be systemically administered.
In the case of a rash in the area surrounding the eye,
consult an ophthalmologist in consideration of prob-
able complication with herpes corneae.
(3) Ophthalmological diseases: Potential ophthal-
mological diseases include cataract, retinal detach-
ment, blepharitis, keratoconjunctivitis, and kerato-
conus. It is important to treat rashes in the eye area
and allergic keratoconjunctivitis appropriately since
infancy or childhood in liaison with an ophthalmolo-
gist.
10.2. Other Precautions
1) Referral to a specialist: If the rash does not im-
prove after 1 month of treatment in accordance with
the “Guidelines for the Management of Atopic Der-
matitis 2012 (ADGL 2012),” referral of the patient to a
specialist (e.g., a specialist in cutaneous allergy, a
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Fig.　10　Rashes likely to require referral to a specialis. (A) Body trunk and upper limb in an infant: 
marked erythema, desquamation, and scratch marks, (B) Body trunk in a child: marked erythema, 
scratch marks, and erosion, (C) Popliteal fossa in a child: erythema, scratch marks, and marked lichenifi -
cation, (D) Head and neck in an adult: prurigo, (E) Lower leg in an adult: marked lichenifi cation and 
scratch marks, (F) Lower limb in an adult: papule with marked scratch marks.
A D
B E
C F
specialist in childhood allergy) or a specialized insti-
tution should be considered. Figure 10 shows specific
examples of rashes requiring referral to a specialist.
2) Hospital treatment: In principle, hospital treat-
ment should be considered for patients with the most
severe cases in the severity index defined in the
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Fig.　11　Rashes likely to require hospitalization. (A) Upper limb: marked desquamation, erythema, and 
scratch mark, (B) Body trunk: marked desquamation, erythema, and scratch marks, and lichenifi cation, 
(C) Lower limb: marked desquamation, erythema, scratch marks, and lichenifi cation, (D) Neck and ante-
rior chest: marked erythema, desquamation, erosion, and scratch marks, (E) Upper limb: marked erythe-
ma, desquamation, erosion, scratch marks, and lichenifi cation, (F) Lower limb: marked erythema, des-
quamation, erosion, scratch marks, and lichenifi cation.
A D
B E
C F
ADGL 2012. Figure 11 shows specific examples of
cases requiring hospitalization.
3) Precautions in children: The ADGL 2012 de-
scribe the oral administration of steroids for the most
severe case as a measure “to be taken temporarily as
needed.” However, affected children, particularly
those cases complicated by asthma, require a close
liaison with a specialist (e.g. a specialist in cutaneous
allergy, a specialist in childhood allergy), since dis-
continuation of the oral administration of steroids
may aggravate the symptoms (Fig. 12).
4) Precautions for oral steroids: Oral steroids
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Fig.　12　Cutaneous symptoms of children requiring referral to a specialized medical institu-
tion. (A) Face of an infant (9 months old): Aggravation by steroid withdrawal. Extreme fl ush 
and erosion on the face, (B) Forearm of an infant (4 months old): Edematous and erosive 
fl ush, (C) Scalp of an infant (4 months old): Red papule and crust spreading over the head, 
(D) Cheek and ear of an infant (4 months old): Marked weeping fl ush and edema on the face 
and neck, (E) Neck and shoulder of a child (9 years old): Severely scratching multiple num-
mular eczema, (F) Femurs of a child (9 years old): Lichenifi cation and pruritic tubercles due 
to poor compliance with application of steroid.
A D
B E
C F
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should not be used at all or should be used with con-
sideration of the minimum dose and the duration of
use.
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